CDKN2A 表达增加在小细胞肺癌中的临床意义及潜在机制。

Clinical significance and prospective mechanism of increased CDKN2A expression in small cell lung cancer.

机构信息

Department of Pathology, The First Affiliated Hospital of Guangxi Medical University, Guangxi Zhuang Autonomous Region, Nanning, People's Republic of China.

Cardiothoracic Surgery, The First Affiliated Hospital of Guangxi Medical University, Guangxi Zhuang Autonomous Region, Nanning, People's Republic of China.

出版信息

Clin Transl Oncol. 2024 Jun;26(6):1519-1531. doi: 10.1007/s12094-023-03376-2. Epub 2024 Jan 11.

DOI:10.1007/s12094-023-03376-2

PMID:38206516

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11108933/

Abstract

BACKGROUND

Although it has been shown that cyclin dependent kinase inhibitor 2A (CDKN2A) plays a significant role in a number of malignancies, its clinicopathological value and function in small cell lung cancer (SCLC) is unclear and warrants additional research.

METHODS

The clinical significance of CDKN2A expression in SCLC was examined by multiple methods, including comprehensive integration of mRNA level by high throughput data, Kaplan-Meier survival analysis for prognostic value, and validation of its protein expression using in-house immunohistochemistry.

RESULTS

The expression of CDKN2A mRNA in 357 cases of SCLC was evidently higher than that in the control group (n = 525) combing the data from 20 research centers worldwide. The standardized mean difference (SMD) was 3.07, and the area under the curve (AUC) of summary receiver operating characteristic curve (sROC) was 0.97 for the overexpression of CDKN2A. ACC, COAD, KICH, KIRC, PCPG, PRAD, UCEC, UVM patients with higher CDKN2A expression had considerably worse overall survival rates than those with lower CDKN2A expression with the hazard ratio (HR) > 1.

CONCLUSION

CDKN2A upregulation extensively enhances the carcinogenesis and progression of SCLC.

摘要

背景

虽然细胞周期蛋白依赖性激酶抑制剂 2A（CDKN2A）已被证明在多种恶性肿瘤中发挥重要作用，但它在小细胞肺癌（SCLC）中的临床病理价值和功能尚不清楚，需要进一步研究。

方法

通过多种方法研究 CDKN2A 在 SCLC 中的表达的临床意义，包括高通量数据综合整合 mRNA 水平、Kaplan-Meier 生存分析预测价值，以及使用内部免疫组织化学验证其蛋白表达。

结果

将全球 20 个研究中心的数据结合起来，在 357 例 SCLC 病例中 CDKN2A mRNA 的表达明显高于对照组（n=525）。标准化均数差（SMD）为 3.07，CDKN2A 过表达的汇总受试者工作特征曲线（sROC）曲线下面积（AUC）为 0.97。ACC、COAD、KICH、KIRC、PCPG、PRAD、UCEC、UVM 患者中 CDKN2A 表达较高的患者总生存率明显低于 CDKN2A 表达较低的患者，风险比（HR）>1。